Trump promised cheaper drugs. Some prices dropped. Many others shot up.

Since the beginning of his second term, President Trump has been actively addressing the rising costs of prescription drugs in the United States. This comes as no surprise, as a recent KFF poll revealed that a majority of American adults are concerned about affording their medication, with over 80% considering drug prices unreasonable. Compared to other countries, Americans pay significantly more for the same prescription drugs.

In an effort to tackle this issue, President Trump initiated discussions with pharmaceutical companies to lower drug prices voluntarily. He also negotiated with several pharmaceutical executives to implement “most favored nation” pricing on Medicaid, which provides coverage for low-income Americans. Additionally, the unveiling of TrumpRx, a website offering discounted medicines for cash-paying patients, aimed to provide more affordable options for those in need.

However, the effectiveness of these initiatives remains uncertain, with many details of the negotiations still unclear. White House spokesperson Kush Desai did not provide specific information about TrumpRx, leaving many questions unanswered. While some patients may benefit from these programs, the overall impact is limited, as access to discounts may require specific knowledge and resources.

Notable figures like billionaire investor Mark Cuban have also entered the conversation on lowering drug prices. Cuban’s Cost Plus Drugs initiative focuses on selling affordable generic medications by eliminating middlemen and offering direct-to-consumer sales. Despite these efforts, experts like Aaron Kesselheim from Harvard Medical School believe that the current agreements made by the Trump administration are more for publicity and lack transparency and enforceability.

Although President Trump’s negotiations with pharmaceutical companies have resulted in some discounts on certain drugs, the overall impact on drug pricing remains minimal. Data from consulting firm 46brooklyn shows that drug prices continue to rise, with the highest number of list price increases recorded in 2025. However, a significant development has been the continuation of a Biden administration program that allows for Medicare drug price negotiation, resulting in substantial savings for Medicare patients.

While these negotiated discounts benefit Medicare enrollees, the broader impact on drug pricing and accessibility remains a challenge. Industry lobbyists have pushed back on certain aspects of the negotiation agreements, limiting their effectiveness. Despite these challenges, the United States has taken a significant step by negotiating drug prices, aligning with other developed countries’ practices.

In conclusion, while efforts are being made to lower prescription drug prices in the United States, the road ahead is challenging. The Trump administration’s initiatives, along with ongoing negotiations and agreements, aim to provide relief to patients struggling with high drug costs. However, the complexity of the pharmaceutical industry and the various factors influencing drug pricing make it a nuanced and ongoing issue that requires continued attention and action.